Proving the Business Case for the Internet of Things

Cytta and CardioComm form telemedicine joint venture

Steve Rogerson
October 24, 2017

Las Vegas-based smartphone and web based healthcare technology company Cytta has formed a joint venture with Canadian heart monitoring and electrocardiogram software and hardware firm CardioComm to implement a mobile telemedicine communications and connectivity health and wellness portal.
The portal builds on Cytta’s EvrCare branded Veri smartphone web-based remote patient monitoring platform. EvrCare also leverages Cytta’s video and data compression-decompression system known as Super, for Superior Utilisation of Processing for Error Resilience, which reduces data file size, improves speed of data transfers, lowers telemedicine communications costs and introduces a level of data transmission security.
Cytta selected CardioComm to augment its existing mhealth, telemedicine and IoT remote patient monitoring due to CardioComm’s expertise in supplying ECG monitoring devices, connectivity and ECG reviewing software that are cleared as Class II medical devices by the US FDA and Health Canada regulatory authorities.
CardioComm’s software as a medical device (SaaMD) ECG products can accept raw ECG data from any Bluetooth enabled ECG devices to generate an accurate ECG trace rendered on a scaled grid, delivered with information that is specific to the individual the ECG was recorded from as well as those who reviewed and reported the ECG findings.
All reports, findings and associated patient information would be managed within the EvrCare telemedicine platform which will incorporate CardioComm’s ECG analysis tools and provide the ECG findings along with data from all other EvrCare connected health and wellness peripherals that were used to monitor patients or used by consumers for self monitoring.
Cytta was also drawn to CardioComm’s potential to add multiple bio-sign monitoring under its Class II medical device clearances and thereby potentially cover the EvrCare branded platform services under a SaaMD classification.
ErvCare is expected to provide single users as well as group plan operators the ability to track, evaluate and manage biometric information seamlessly, concurrently and in real time from all connected health and wellness devices.
Cytta plans to incorporate a doctor-directed platform where devices themselves can be prescribed by caregivers and insurers to improve long-term care in managing people at high risk for disease onset and those living with chronic medical conditions. Cytta anticipates the addition of the CardioComm ECG hardware and software to the EvrCare platform will provide a valuable and potentially lifesaving functionality to US healthcare consumers.
The EvrCare and ECG development work are intended to be the first phase of a multiphase programme between CardioComm and Cytta’s IoT telemedicine service. Incorporation of CardioComm’s ECG monitoring capabilities could help remove many of the technological, work flow and infrastructure challenges that exist in remote patient monitoring for mobile cardiac telemetry, arrhythmia and prolonged QT interval screening and serve to expand EvrCare’s service offerings.
In addition to consumer offering, the technology may be expanded to include in-hospital and in-clinic services, and pre and post-hospital surgery discharge monitoring as well as support long-term and managed care groups in monitoring the insured lives of people living with chronic medical conditions.
The telemedicine platform with ECG management capabilities will be initially deployed in the USA.